Nov 10,2024

World Diabetes Day 2024 : This is Diabetes, This is Well-Being

In celebration of World Diabetes Day 2024, Ascensia Diabetes Care has launched its ninth annual campaign, "This is Diabetes, This is Well-Being," aligning with the International Diabetes Federation's theme of "Diabetes and Well-being." Ascensia has created a virtual wellness zone at www.thisisdiabetes.com, where an expert panel of endocrinologists, psychologists, and dietitians answer questions about diabetes care and well-being. People with diabetes and their families can submit questions until November 21, with responses published until the end of the month. The campaign aims to foster a sense of community and provide valuable insights into managing the physical, mental, and societal aspects of diabetes.

View Analyst & Ambassador Comments
Go to original news
Aug 14,2024

Saudi Arabia Digital Diabetes Management Market Trends Analysis Report 2024-2030

The "Saudi Arabia Digital Diabetes Management Market Size, Share & Trends Analysis Report" forecasts that the market will reach USD 208.3 million by 2030, growing at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2030. The growth is driven by the rising prevalence of type 2 diabetes, influenced by sedentary lifestyles and poor dietary habits, along with the increased adoption of digital health solutions like wearable devices and mobile apps. In 2023, continuous glucose monitoring systems held the largest market share, while smart insulin pens and wearable devices are expected to see significant growth. The home settings segment, where individuals manage their diabetes privately, is also growing rapidly.

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 15,2024

Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 20...

Glucotrack, Inc. (Nasdaq: GCTK) presented new findings from a market research study on its Continuous Blood Glucose Monitor (CBGM) concept at the 2024 ADCES Annual Conference. The study found that over 50% of respondents with insulin-requiring diabetes are open to adopting Glucotrack’s CBGM, a small implantable device that offers continuous glucose monitoring for up to three years without the calibration and wearability issues of traditional systems. Key features, including long sensor life, no wearable component, and real-time readings, were highly appealing. The study involved 757 participants with type 1 and type 2 diabetes, including current, former, and non-users of Continuous Glucose Monitors. Glucotrack aims to refine the CBGM technology further, with preclinical studies demonstrating promising accuracy for the device.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 14,2024

Food as Medicine: Nutrisense's Award-Winning Approach to Data-Driven Nutrition

Nutrisense, a company focused on personalized, data-driven nutrition, has been recognized with the “Best Food as Medicine Company” award at the HLTH USA Conference for its innovative approach to improving health through food. The company emphasizes personalized, science-backed guidance over generic diets, using tools like continuous glucose monitors (CGMs) to help individuals understand how different foods affect their health. Nutrisense’s team of expert dietitians provides tailored advice to help manage chronic conditions such as type 2 diabetes, obesity, and hypertension. Their "Food as Medicine" philosophy empowers people to use food to improve their health and prevent disease, rather than relying on restrictive diets. This approach is supported by real-time data and the expertise of dietitians, making it a holistic, sustainable path to long-term well-being.

View Analyst & Ambassador Comments
Go to original news
Aug 15,2024

Connected Diabetes Care Innovations and Growth Opportunities 2024: Funding, Emerging Technologies, and Key Partnerships Shaping the Future

The "Connected Diabetes Care: Innovations and Growth Opportunities" report explores advancements in continuous glucose monitors (CGMs), insulin delivery technologies, and artificial pancreas systems. It highlights the increasing preference for wearable CGMs over traditional finger-stick testing, especially for type 1 diabetes (T1D). The report also covers emerging digital diabetes care technologies, such as AI-driven apps that predict blood glucose levels and support overall well-being. Key growth opportunities identified include noninvasive glucose sensors, miniaturized artificial pancreas systems, and oral insulin. It also discusses funding trends, partnerships, and their impact on the future of diabetes care.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 15,2024

ACON participated Medica 2024 in Düsseldorf, German during 11th to 14th Nov

ACON participated in MEDICA 2024, held in Düsseldorf, Germany, from November 11th to 14th. The 56th International Medical Equipment Exhibition showcased innovation in the medical field, drawing global attention from healthcare industry leaders. With the growing demand for medical supplies and accelerating technological advancements, MEDICA 2024 highlighted emerging trends and innovations in healthcare.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 13,2024

Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care

Ypsomed reported strong growth in the first half of the 2024/25 financial year, achieving consolidated sales of CHF 324 million, up from CHF 255.4 million the previous year. This 29.9% growth was driven by the delivery of injection systems, including autoinjectors and pens, as well as the mylife YpsoPump. The company also made strategic moves, including the sale of its pen needle and blood glucose monitoring (BGM) businesses to focus on its core Delivery Systems division. Ypsomed is expanding production in Switzerland, Germany, and China to support future growth. The Diabetes Care division also saw significant growth, with mylife YpsoPump reaching 60,000 active users. The company plans to further develop its Diabetes Care business as an independent entity.

View Analyst & Ambassador Comments
Go to original news
Nov 12,2024

Terumo Blood and Cell Technologies Merges Therapeutics Units to Enhance Patient Care Across Treatment Journey New Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to un...

Terumo Blood and Cell Technologies (Terumo BCT) has launched its new Global Therapy Innovations business unit to enhance patient care across various disease areas, including sickle cell disease (SCD), immuno-oncology, and more. Led by Veerle d'Haenens, this unit will streamline knowledge sharing and integrate solutions across the patient journey, from cell collection to therapy delivery. The unit will leverage technologies like the Spectra Optia™ Apheresis System and Quantum Flex™ Cell Expansion System to improve therapeutic apheresis and cell and gene therapies (CGTs). It aims to optimize patient access to therapies, particularly in areas with high unmet needs, and enhance the entire treatment process, from cell collection to therapy delivery. Terumo BCT’s collaborations with experts and CGT developers aim to address challenges and improve outcomes for patients with complex conditions.

View Analyst & Ambassador Comments
Go to original news
Nov 11,2024

Insulin Pump Market Outlook 2024-2035: Key Players and Trends

The global insulin pump market is projected to reach USD 5.8 billion by 2024, with an expected growth rate of 8% annually through 2035. The market includes various types of pumps, such as tethered and patch pumps, with advancements in automation and battery technology driving innovation. Insulin pumps offer precise, continuous insulin delivery, enhancing diabetes management and improving patients' quality of life by reducing the risks associated with traditional insulin injections. The market report covers trends, key players, and growth opportunities in regions like North America, Europe, and Asia-Pacific.

View Analyst & Ambassador Comments
Go to original news
Nov 12,2024

Insulin Pens Market Size to Surpass USD 14.72 Billion by 2033

The global insulin pen market, valued at USD 7.46 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 7.84% through 2033. Insulin pens, which are increasingly preferred over syringes for their convenience and accuracy in delivering insulin, are driving market growth. The demand for smart insulin pens, which offer enhanced diabetes management through continuous monitoring, is also rising, especially in Europe. Key market players include Lilly, Medtronic, Novo Nordisk, and others. Europe is expected to maintain a significant market share, with innovations like Bluetooth-enabled pens contributing to growth.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES